Hudis CA - Search Results

1

Breast cancer risk reduction: no pain, no gain?

Hudis CA, Subbaramaiah K, Morris PG, Dannenberg AJ. Hudis CA, et al. J Clin Oncol. 2012 Oct 1;30(28):3436-8. doi: 10.1200/JCO.2012.44.8597. Epub 2012 Aug 27. J Clin Oncol. 2012. PMID: 22927528 No abstract available.

2

Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ. Howe LR, et al. Cancer Res. 2002 Oct 1;62(19):5405-7. Cancer Res. 2002. PMID: 12359744

3

Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.

Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Among authors: hudis ca. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4062-7. doi: 10.1158/1078-0432.CCR-03-0463. Clin Cancer Res. 2004. PMID: 15217939 Clinical Trial.

4

HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.

Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD, Newman RA, Yang P, Thaler HT, Muller WJ, Hudis C, Brown AM, Hla T, Subbaramaiah K, Dannenberg AJ. Howe LR, et al. Cancer Res. 2005 Nov 1;65(21):10113-9. doi: 10.1158/0008-5472.CAN-05-1524. Cancer Res. 2005. PMID: 16267038

5

HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.

Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ. Subbaramaiah K, et al. Cancer Res. 2006 May 15;66(10):5504-11. doi: 10.1158/0008-5472.CAN-05-4076. Cancer Res. 2006. PMID: 16707480

6

EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange.

Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. Subbaramaiah K, et al. J Biol Chem. 2008 Feb 8;283(6):3433-3444. doi: 10.1074/jbc.M705409200. Epub 2007 Dec 14. J Biol Chem. 2008. PMID: 18083712 Free article. Retracted.

7

Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter.

Morris PG, Hudis CA. Morris PG, et al. Among authors: hudis ca. Breast Cancer Res Treat. 2011 Jun;127(2):585-6. doi: 10.1007/s10549-008-0172-5. Epub 2008 Sep 13. Breast Cancer Res Treat. 2011. PMID: 18791822 No abstract available.

8

Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription.

Subbaramaiah K, Benezra R, Hudis C, Dannenberg AJ. Subbaramaiah K, et al. J Biol Chem. 2008 Dec 5;283(49):33955-68. doi: 10.1074/jbc.M805490200. Epub 2008 Oct 8. J Biol Chem. 2008. PMID: 18842581 Free PMC article. Retracted.

9

Therapeutic options for metastatic breast cancer.

Morris PG, McArthur HL, Hudis CA. Morris PG, et al. Among authors: hudis ca. Expert Opin Pharmacother. 2009 Apr;10(6):967-81. doi: 10.1517/14656560902834961. Expert Opin Pharmacother. 2009. PMID: 19351274 Review.

10

Personalizing therapy for metastatic breast cancer.

Morris PG, Hudis CA. Morris PG, et al. Among authors: hudis ca. Expert Rev Anticancer Ther. 2009 Sep;9(9):1223-6. doi: 10.1586/era.09.89. Expert Rev Anticancer Ther. 2009. PMID: 19761426

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

471 results

Search Page